Turning Point Therapeutics, Inc. Common Stock
TPTX
TPTX was delisted on the 16th of August, 2022.
190 hedge funds and large institutions have $3.58B invested in Turning Point Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 101 increasing their positions, 39 reducing their positions, and 38 closing their positions.
159% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 39
6% less funds holding
Funds holding: 202 → 190 (-12)
15% less capital invested
Capital invested by funds: $4.21B → $3.58B (-$626M)
32% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 38
48% less call options, than puts
Call options by funds: $1.5M | Put options by funds: $2.89M
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$99.6M |
| 2 |
BlackRock
New York
|
+$50.1M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
+$36.6M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$28.3M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$27.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$245M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$47M |
| 3 |
CCM
Consonance Capital Management
New York
|
-$42.6M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$33.7M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$19.4M |
TPTX Hedge Fund Activity: Q2 2021 in Review
190 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Turning Point Therapeutics, Inc. Common Stock (TPTX) for Q2 2021, worth a combined $3.58B — down 15% from $4.21B a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of TPTX and 26 opened new positions — a net loss of 12 holders — while 39 trimmed existing stakes and 101 added.
The largest buyer was Wellington Management Group, adding an estimated $99.6M. The largest seller was Fidelity Investments, cutting an estimated $245M.
- 190 institutional investors held Turning Point Therapeutics, Inc. Common Stock (TPTX) as of Q2 2021, down from 202 in Q1 2021.
- Funds reported $3.58B of Turning Point Therapeutics, Inc. Common Stock stock for Q2 2021, down 15% quarter-over-quarter.
- 26 funds opened new Turning Point Therapeutics, Inc. Common Stock positions in Q2 2021 and 38 closed out, a net change of -12 holders.
- The largest Turning Point Therapeutics, Inc. Common Stock buyer in Q2 2021 was Wellington Management Group, an estimated $99.6M added.
- The largest Turning Point Therapeutics, Inc. Common Stock seller in Q2 2021 was Fidelity Investments, an estimated $245M sold.
Based on aggregated 13F filings for Q2 2021.